| mRNA |
lenvatinib |
CTRPv2 |
pan-cancer |
AAC |
-0.0038 |
0.9 |
| mRNA |
RAF265 |
FIMM |
pan-cancer |
AAC |
-0.017 |
0.9 |
| mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0034 |
0.9 |
| mRNA |
Rapamycin |
GDSC1000 |
pan-cancer |
AAC |
0.005 |
0.9 |
| mRNA |
Lisitinib |
GDSC1000 |
pan-cancer |
AAC |
-0.0032 |
0.9 |
| mRNA |
BRD-K84807411 |
CTRPv2 |
pan-cancer |
AAC |
0.007 |
0.9 |
| mRNA |
SR-II-138A |
CTRPv2 |
pan-cancer |
AAC |
-0.003 |
0.9 |
| mRNA |
AGK-2 |
CTRPv2 |
pan-cancer |
AAC |
0.0035 |
0.9 |
| mRNA |
tretinoin:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0032 |
0.9 |
| mRNA |
BRD-K24690302 |
CTRPv2 |
pan-cancer |
AAC |
0.0033 |
0.9 |